- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Latest Conference Articles
Psychological Interventions Can Lower Fear of Recurrence
June 2nd 2017, 11:47pm
A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.
Combination Improves Breast Cancer Survival, Study Shows
June 2nd 2017, 11:07pm
Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.
Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer
March 15th 2017, 9:19pm
SGO Annual Meeting on Women's Cancer
Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.
Improving Survival in BRCA-Proficient Ovarian Cancer
March 15th 2017, 8:20pm
SGO Annual Meeting on Women's Cancer
Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.
Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer
March 15th 2017, 6:41pm
SGO Annual Meeting on Women's Cancer
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer
March 15th 2017, 4:52pm
SGO Annual Meeting on Women's Cancer
PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.
Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
March 15th 2017, 12:37am
SGO Annual Meeting on Women's Cancer
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status
March 14th 2017, 10:32pm
SGO Annual Meeting on Women's Cancer
The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.
Declining Concern about HPV Vaccine and Sexual Activity
March 13th 2017, 11:53pm
SGO Annual Meeting on Women's Cancer
Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.
Genetic Counseling and Ovarian Cancer: 4 Questions With an Expert
March 13th 2017, 10:26pm
SGO Annual Meeting on Women's Cancer
Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.
Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer
March 13th 2017, 9:31pm
SGO Annual Meeting on Women's Cancer
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
Rucaparib Shows Promising Activity in Recurrent Ovarian Cancer
March 13th 2017, 8:59pm
SGO Annual Meeting on Women's Cancer
Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.
Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer
March 13th 2017, 1:12am
SGO Annual Meeting on Women's Cancer
Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.